Discover and read the best of Twitter Threads about #ECCMID2022
Most recents (8)
ATTACK Trial results #ECCMID2022: efficacy & safety of sulbactam-durlobactam (SUL-DUR) vs colistin for Acinetobacter baumannii complex. Sulbactam has intrinsic activity against AB (PBP binding); durlobactam potent inhibition of class A, C,D beta-lactamases
pubmed.ncbi.nlm.nih.gov/28665414/
pubmed.ncbi.nlm.nih.gov/28665414/
this was a phase 3 non-inferiority trial of HAP, VAP, BSI randomized 1:1 to SUL-DUR plus IMI or Colistin + IMI. primary efficacy outcome 28-day ACM, safety = nephrotoxicity measured by RIFLE #ECCMID2022
study enrollment was as follows, 95% of isolates were CRAB #ECCMID2022
🤩
Next up at #ECCMID2022 Dr. Bonomo…
👀 Watch out here come the 🧠 💣 knowledge bombs!!!
#BadBugsNeedDrugs #SaveABX
🗣 Starts by emphasizing the importance of distilling the information, discusses GUIDELINES that uses grading vs GUIDANCE of experts
Next up at #ECCMID2022 Dr. Bonomo…
👀 Watch out here come the 🧠 💣 knowledge bombs!!!
#BadBugsNeedDrugs #SaveABX
🗣 Starts by emphasizing the importance of distilling the information, discusses GUIDELINES that uses grading vs GUIDANCE of experts
Dr. Bonomo:
Starting with definitions is important so we set the stage and are speaking the same language.
Is MDR to me why MDR is to you? Great point to level set first.
#ECCMID2022
Starting with definitions is important so we set the stage and are speaking the same language.
Is MDR to me why MDR is to you? Great point to level set first.
#ECCMID2022
“Eravacycline - what part of no don’t you understand?”
Dr. Bonomo says with levity on DTR Pseudomonas infection management 😂
#ECCMID2022
Dr. Bonomo says with levity on DTR Pseudomonas infection management 😂
#ECCMID2022
Late breaker session at #ECCMID2022 on acute hepatitis cases of unknown origin in children.
So far, 169 cases have been reported from 11 countries since first case was identified in 31 March. 17 have required liver transplant & at least one death has been reported. #IDTwitter
So far, 169 cases have been reported from 11 countries since first case was identified in 31 March. 17 have required liver transplant & at least one death has been reported. #IDTwitter
Almost all cases had high transaminases, majority of children have been hospitalised. No common exposure has been identified, no link to COVID19 vaccination. Adenovirus F41 was identified in several cases, but it doesn’t fully explain the clinical severity observed. #ECCMID2022
But there are still many uncertainties about acute hepatitis cases observed. Especially the # of cases, exact age group, clinical presentation, uncertain test results as not all cases were tested for adenovirus, risk factors and transmission routes remain unclear. #ECCMID2022
SABATO has been going on for quite a while now!
Question: is switching to oral therapy for low risk SAB possible?
Low risk: negative follow-up BC, no mestatistic infection, intravascular catheters removed, no prosthetic vascular material, not immunosuppressed
Question: is switching to oral therapy for low risk SAB possible?
Low risk: negative follow-up BC, no mestatistic infection, intravascular catheters removed, no prosthetic vascular material, not immunosuppressed
Benefits and risks:
🤔 📖 📱
Is Twitter The New ID Textbook?
Bugs, Drugs, and Social Media – Twitter as a Tool for Advancing the Field of Infectious Diseases
My #ECCMID2022 slides as a 🧵 1/n
Is Twitter The New ID Textbook?
Bugs, Drugs, and Social Media – Twitter as a Tool for Advancing the Field of Infectious Diseases
My #ECCMID2022 slides as a 🧵 1/n
Many ingredients in the kitchen of social media can be combined to create different products which supports advancing ID through SM.
Each activity can support one or multiple domains of 🧠 Blooms Taxonomy.
Get creative with your recipes to create new fun stuff! 2/n
Each activity can support one or multiple domains of 🧠 Blooms Taxonomy.
Get creative with your recipes to create new fun stuff! 2/n
One of the best accounts out there on SM @DGlaucomflecken - huge reach in short period, recent ASP skit in vertical video, very entertaining & original, uses several SM platforms.
REMEMBERING domain: ⚠️ beware inappropriate meropenem prescribing.
3/n
REMEMBERING domain: ⚠️ beware inappropriate meropenem prescribing.
3/n
📸 Now watching @EckerleIsabella about to talk here virtually at #ECCMID2022 @ESCMID
😃 Have been looking forward to this!
💬💬💬 Lots of comments at SM talks on how @Twitter is the primary platform for scientists
#IDtwitter #EpiTwitter #MedTwitter #TwitteRx
😃 Have been looking forward to this!
💬💬💬 Lots of comments at SM talks on how @Twitter is the primary platform for scientists
#IDtwitter #EpiTwitter #MedTwitter #TwitteRx
⚠️⬇️🚨🤔🤣🔴✅📢❌▶️
Emoji use evaluated in misinformation tweets! Very interesting!!
@EckerleIsabella at #ECCMID2022 @ABsteward
Emoji use evaluated in misinformation tweets! Very interesting!!
@EckerleIsabella at #ECCMID2022 @ABsteward
🤩 Excited to see Dr. John Turnidge present in person at #ECCMID2022
He has 186 hits in pubmed and is a co-author on one of my favorite papers: “MIC-based dose adjustment: facts and fables”
pubmed.ncbi.nlm.nih.gov/29216348/
#BossLevel #Twitter
He has 186 hits in pubmed and is a co-author on one of my favorite papers: “MIC-based dose adjustment: facts and fables”
pubmed.ncbi.nlm.nih.gov/29216348/
#BossLevel #Twitter
New #SIREN🚨 preprint out (and also being presented at #ECCMID2022 this week)...we did a cross-sectional analysis of ~6,000 SIREN participants after their vaccinations
Thread on our results and few interesting ones...🧵
medrxiv.org/content/10.110… @UKHSA @SMHopkins
Thread on our results and few interesting ones...🧵
medrxiv.org/content/10.110… @UKHSA @SMHopkins
First up, SIREN is an incredibly big research project...so we were able to select samples from participants that provided a baseline sample (done when enrolled into SIREN) but after they were vaccinated, giving us an initial pool of ~6,000 participants...
All samples were then tested for anti-spike and anti-nucleocapsid antibodies
We then split these participants into 3 groups: naive (no PCR+), those with history of a PCR+, and then those with no PCR+ history but anti-N positive
(but more on why this is important later)
We then split these participants into 3 groups: naive (no PCR+), those with history of a PCR+, and then those with no PCR+ history but anti-N positive
(but more on why this is important later)
